Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Depreciation & Amortization (CF) (2022 - 2025)

Historic Depreciation & Amortization (CF) for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $120000.0.

  • Axsome Therapeutics' Depreciation & Amortization (CF) fell 839.69% to $120000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $518000.0, marking a year-over-year decrease of 335.82%. This contributed to the annual value of $532000.0 for FY2024, which is 1590.41% up from last year.
  • Latest data reveals that Axsome Therapeutics reported Depreciation & Amortization (CF) of $120000.0 as of Q3 2025, which was down 839.69% from $120000.0 recorded in Q2 2025.
  • Axsome Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $149000.0 for Q1 2025, and its period low was $37000.0 during Q1 2022.
  • For the 4-year period, Axsome Therapeutics' Depreciation & Amortization (CF) averaged around $109533.3, with its median value being $120000.0 (2025).
  • As far as peak fluctuations go, Axsome Therapeutics' Depreciation & Amortization (CF) soared by 14324.32% in 2023, and later crashed by 1428.57% in 2025.
  • Quarter analysis of 4 years shows Axsome Therapeutics' Depreciation & Amortization (CF) stood at $85000.0 in 2022, then soared by 56.47% to $133000.0 in 2023, then decreased by 3.01% to $129000.0 in 2024, then dropped by 6.98% to $120000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $120000.0 for Q3 2025, versus $120000.0 for Q2 2025 and $149000.0 for Q1 2025.